Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms

Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers

(2015) Benjamin R. Waterhouse et al.   Oncotarget

Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer

(2012) Said Akli et al.   CELL CYCLE

PKC-dependent phosphorylation of p27 at T198 contributes to p27 stabilization and cell cycle arrest

(2012) Fernanda De Vita et al.   CELL CYCLE

New light on p27kip1 in breast cancer

(2012) Barbara Belletti et al.   CELL CYCLE

Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo

(2012) F. Simpkins et al.   CLINICAL CANCER RESEARCH

Estrogen Receptors β1 and β2 Have Opposing Roles in Regulating Proliferation and Bone Metastasis Genes in the Prostate Cancer Cell Line PC3

(2012) Prasenjit Dey et al.   MOLECULAR ENDOCRINOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Lapatinib, a Preventive/Therapeutic Agent against Mammary Cancer, Suppresses RTK-Mediated Signaling through Multiple Signaling Pathways

(2011) J. Li et al.   Cancer Prevention Research

CARM1 Is an Important Determinant of ER -Dependent Breast Cancer Cell Differentiation and Proliferation in Breast Cancer Cells

(2011) M. Al-Dhaheri et al.   CANCER RESEARCH

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

(2010) Roque Diaz et al.   BMC CANCER

Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers

(2010) Max Yan et al.   BREAST CANCER RESEARCH AND TREATMENT

ERβ Impedes Prostate Cancer EMT by Destabilizing HIF-1α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading

(2010) Paul Mak et al.   CANCER CELL

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells

(2009) Amelia D’Alessio et al.   BREAST CANCER RESEARCH AND TREATMENT

p27Kip1 as a prognostic factor in breast cancer: a systematic review and meta-analysis

(2009) Xiaoxiang Guan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

(2008) Jin Won Kim et al.   CANCER LETTERS

Nuclear and Cytoplasmic Expression of ER 1, ER 2, and ER 5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients

(2008) A. M. Shaaban et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

ERβ in breast cancer—Onlooker, passive player, or active protector?

(2008) Emily M. Fox et al.   STEROIDS